Head-to-head comparison of ¹⁸F-FAPI and ¹⁸F-FDG PET/CT in staging and therapeutic management of hepatocellular carcinoma.

ABSTRACT:

Background

Fluorine 18 (¹⁸F) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has limitations in staging hepatocellular carcinoma (HCC). The recently introduced ¹⁸F-labeled fibroblast-activation protein inhibitor (FAPI) has shown promising prospects in detection of HCC lesions. This study aimed to investigate the initial staging and restaging performance of ¹⁸F-FAPI PET/CT compared to ¹⁸F-FDG PET/CT in HCC.

Methods

This prospective study enrolled histologically confirmed HCC patients from March 2021 to September 2022. All patients were examined with ¹⁸F-FDG PET/CT and ¹⁸F-FAPI PET/CT within 1 week. The maximum standard uptake value (SUV_max), tumor-to-background rati

SUBMITTER: Zhang J 

PROVIDER: S-EPMC10614420 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature